OCULAR THERAPEUTIX, INC Increase (Decrease) in Derivative Liabilities
OCULAR THERAPEUTIX, INC (OCUL) reported Increase (Decrease) in Derivative Liabilities of $6.32 million for the 2-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDerivativeLiabilities · last filed 2023-11-07
- OCULAR THERAPEUTIX, INC increase (decrease) in derivative liabilities for the quarter ending 2023-06-30 was $1.13M, a 59.21% decline year-over-year.
- OCULAR THERAPEUTIX, INC increase (decrease) in derivative liabilities for the quarter ending 2023-03-31 was -$6.56M, a 194.32% decline year-over-year.
- OCULAR THERAPEUTIX, INC increase (decrease) in derivative liabilities for the quarter ending 2022-12-31 was $5.24M, a 66.97% decline year-over-year.
- OCULAR THERAPEUTIX, INC increase (decrease) in derivative liabilities for the quarter ending 2022-09-30 was -$1.13M, a 104.75% decline year-over-year.
- OCULAR THERAPEUTIX, INC increase (decrease) in derivative liabilities for fiscal 2022 was $13.84M, a 82.28% decline from fiscal 2021.
- OCULAR THERAPEUTIX, INC increase (decrease) in derivative liabilities for fiscal 2021 was $78.12M.
- OCULAR THERAPEUTIX, INC increase (decrease) in derivative liabilities for fiscal 2020 was -$86.19M, a 2099.74% decline from fiscal 2019.
- OCULAR THERAPEUTIX, INC increase (decrease) in derivative liabilities for fiscal 2019 was $4.31M.
| Period end | Increase (Decrease) in Derivative Liabilities 2 month | Increase (Decrease) in Derivative Liabilities 3 month | Increase (Decrease) in Derivative Liabilities 6 month | Increase (Decrease) in Derivative Liabilities 9 month | Increase (Decrease) in Derivative Liabilities 12 month |
|---|---|---|---|---|---|
| 2023-09-30 | $6.32M 10-Q · filed 2023-11-07 | ||||
| 2023-08-31 | $827.00K 10-Q · filed 2023-11-07 | ||||
| 2023-06-30 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-07 | -$5.43M 10-Q · filed 2023-11-07 | -$189.00K derived: sum of 3 quarters · filed 2023-11-07 | -$1.32M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2023-03-31 | -$6.56M 10-Q · filed 2023-05-08 | -$1.32M derived: sum of 2 quarters · filed 2023-05-08 | -$2.45M derived: sum of 3 quarters · filed 2023-05-08 | $320.00K derived: sum of 4 quarters · filed 2023-05-08 | |
| 2022-12-31 | $5.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $4.11M derived: sum of 2 quarters · filed 2023-03-06 | $6.88M derived: sum of 3 quarters · filed 2023-03-06 | $13.84M 10-K · filed 2023-03-06 | |
| 2022-09-30 | -$1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $1.64M derived: sum of 2 quarters · filed 2022-11-07 | $8.60M 10-Q · filed 2022-11-07 | $24.47M derived: sum of 4 quarters · filed 2023-03-06 | |
| 2022-06-30 | $2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $9.73M 10-Q · filed 2022-08-08 | $25.60M derived: sum of 3 quarters · filed 2023-03-06 | $49.44M derived: sum of 4 quarters · filed 2023-03-06 | |
| 2022-03-31 | $6.96M 10-Q · filed 2022-05-09 | $22.83M derived: sum of 2 quarters · filed 2023-03-06 | $46.67M derived: sum of 3 quarters · filed 2023-03-06 | $60.06M derived: sum of 4 quarters · filed 2023-03-06 | |
| 2021-12-31 | $15.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $39.71M derived: sum of 2 quarters · filed 2023-03-06 | $53.10M derived: sum of 3 quarters · filed 2023-03-06 | $78.12M 10-K · filed 2023-03-06 | |
| 2021-09-30 | $23.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $37.23M derived: sum of 2 quarters · filed 2021-11-08 | $62.25M 10-Q · filed 2021-11-08 | -$7.30M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2021-06-30 | $13.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $38.41M 10-Q · filed 2021-08-09 | -$31.14M derived: sum of 3 quarters · filed 2022-02-28 | -$27.37M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2021-03-31 | $25.02M 10-Q · filed 2021-05-05 | -$44.53M derived: sum of 2 quarters · filed 2022-02-28 | -$40.76M derived: sum of 3 quarters · filed 2022-02-28 | -$57.77M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-12-31 | -$69.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$65.78M derived: sum of 2 quarters · filed 2022-02-28 | -$82.78M derived: sum of 3 quarters · filed 2022-02-28 | -$86.19M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $3.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$13.24M derived: sum of 2 quarters · filed 2020-11-05 | -$16.64M 10-Q · filed 2020-11-05 | -$19.66M derived: sum of 4 quarters · filed 2021-03-11 | |
| 2020-06-30 | -$17.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$20.41M 10-Q · filed 2020-08-07 | -$23.43M derived: sum of 3 quarters · filed 2021-03-11 | -$17.72M derived: sum of 4 quarters · filed 2021-03-11 | |
| 2020-03-31 | -$3.40M 10-Q · filed 2020-05-08 | -$6.43M derived: sum of 2 quarters · filed 2021-03-11 | -$711.00K derived: sum of 3 quarters · filed 2021-03-11 | ||
| 2019-12-31 | -$3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $2.69M derived: sum of 2 quarters · filed 2021-03-11 | $4.31M 10-K · filed 2021-03-11 | ||
| 2019-09-30 | $5.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $7.33M 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $1.62M 10-Q · filed 2019-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |